Buspirone Does Not Help with Smoking Cessation
Buspirone is not effective for smoking cessation and should not be used for this purpose. The evidence consistently shows no benefit, and current clinical practice guidelines do not recommend it as a treatment option for tobacco cessation.
Evidence from Guidelines
Multiple authoritative smoking cessation guidelines make no mention of buspirone as a treatment option. The NCCN 2016 guidelines 1, European Cardiovascular Society 2012 guidelines 2, UK Health Education Authority 2000 guidelines 3, US Preventive Services Task Force 2021 4, and Canadian Cardiovascular Society 2025 guidelines 5 all consistently recommend the same first-line pharmacotherapies:
- Nicotine replacement therapy (NRT) - patches combined with short-acting forms (gum, lozenge, inhaler, spray)
- Varenicline
- Bupropion (note: this is bupropion, NOT buspirone - these are different medications)
Buspirone is conspicuously absent from all evidence-based treatment algorithms.
FDA-Approved Indication
The FDA drug label for buspirone 6 clearly states it is "indicated for the management of anxiety disorder or the short-term relief of the symptoms of anxiety." There is no FDA approval or indication for smoking cessation. The label makes no mention of tobacco use or smoking cessation as a potential use.
Research Evidence Shows No Benefit
The research evidence consistently demonstrates buspirone's ineffectiveness:
A 2000 Cochrane systematic review 7 examining anxiolytics for smoking cessation found "no consistent evidence that anxiolytics aid smoking cessation" and specifically noted that two trials of buspirone showed no strong evidence of effect.
An updated 2000 Cochrane review 8 on anxiolytics and antidepressants confirmed "there is little evidence that anxiolytics aid smoking cessation" while noting that bupropion (a different medication) was effective.
Individual RCTs showed mixed or negative results:
- Cinciripini 1995 9: Found buspirone only helped high-anxiety smokers temporarily (while on medication), with effects reversing after discontinuation. By 12 months, abstinence rates were actually lower in the buspirone group (12%) versus placebo (23%) among high-anxiety smokers.
- West 1996 10: Found no treatment differences between buspirone and placebo, with no relief of withdrawal symptoms.
A 2007 study 11 showed benefit only when buspirone was combined with sertraline (an antidepressant), making it impossible to attribute efficacy to buspirone alone.
A 2021 systematic review 12 examining combination pharmacotherapies mentioned buspirone only briefly among "other molecules" with insufficient evidence.
What Actually Works
The evidence-based approach to smoking cessation pharmacotherapy is:
First-Line Options (in order of preference based on efficacy):
- Varenicline - most effective single agent (RR 2.24 vs placebo) 4
- Combination NRT (patch + short-acting form) - highly effective 1, 5
- Bupropion (NOT buspirone) - effective (RR 1.60 vs placebo) 13
Combination Therapy for Heavy Smokers:
- Varenicline + NRT patch - superior to varenicline alone, especially in heavy smokers 1, 12
- Varenicline + bupropion - may be superior to varenicline alone 1
Key Dosing from Guidelines 1:
- Varenicline: Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Weeks 2-12: 1 mg twice daily
- Bupropion: Days 1-3: 150 mg once daily; Day 4 onward: 150 mg twice daily (max 300 mg/day)
- NRT: 21 mg patch + short-acting NRT for breakthrough cravings
Common Pitfall to Avoid
Do not confuse bupropion with buspirone. These are completely different medications:
- Bupropion (Zyban, Wellbutrin) = effective smoking cessation aid, antidepressant
- Buspirone (BuSpar) = anxiolytic with no role in smoking cessation
The similar names cause confusion, but only bupropion has evidence supporting its use for tobacco cessation 13.